Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients

American Journal of Kidney Diseases

Volumn 68, Issue 5, 2016, Pages 763-771

  Luo, Jiacong ^a   Jensen, Donna E ^a   Maroni, Bradley J ^b   Brunelli, Steven M ^a  

^a DAVITA CLINICAL RESEARCH   (United States)

^b AKEBIA THERAPEUTICS   (United States)

Author keywords

Anemia; end stage renal disease (ESRD); erythropoiesis stimulating agent (ESA); ESA dosing; hemodialysis; hemoglobin; hyporesponsiveness; iron utilization

Indexed keywords

ALBUMIN; ANTIANEMIC AGENT; ANTIBIOTIC AGENT; FERRITIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARATHYROID HORMONE; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; VITAMIN D;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EXPOSURE; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEALTH CARE UTILIZATION; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; INCIDENCE; INTENTION TO TREAT ANALYSIS; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MORTALITY RISK; OBSERVATIONAL STUDY; PARATHYROID HORMONE BLOOD LEVEL; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; TRANSFERRIN BLOOD LEVEL; TREATMENT RESPONSE; BLOOD; HEMODIALYSIS; MIDDLE AGED; TREATMENT FAILURE;

AGED; ANEMIA; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 84994885658     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2016.05.031     Document Type: Article

References (28)

1. 1 Zhang, Y., Thamer, M., Stefanik, K., Kaufman, J., Cotter, D.J., Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44 (2004), 866–876.
2. 2 Okazaki, M., Komatsu, M., Kawaguchi, H., Tsuchiya, K., Nitta, K., Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients. Blood Purif 37 (2014), 106–112.
3. 3 Inrig, J.K., Sapp, S., Barnhart, H., et al. Impact of higher hemoglobin targets on blood pressure and clinical outcomes: a secondary analysis of CHOIR. Nephrol Dial Transplant 27 (2012), 3606–3614.
4. 4 Icardi, A., Paoletti, E., De Nicola, L., et al. Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. Nephrol Dial Transplant 28 (2013), 1672–1679.
5. 5 Lopez-Gomez, J.M., Portoles, J.M., Aljama, P., Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl 111 (2008), S75–S81.
6. 6 Kilpatrick, R.D., Critchlow, C.W., Fishbane, S., et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 3 (2008), 1077–1083.
7. 7 Weinhandl, E.D., Gilbertson, D.T., Collins, A.J., Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients. Am J Nephrol 34 (2011), 298–308.
8. 8 Kalantar-Zadeh, K., Lee, G.H., Miller, J.E., et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis 53 (2009), 823–834.
9. 9 McCullough, P.A., Barnhart, H.X., Inrig, J.K., et al. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol 37 (2013), 549–558.
10. 10 Brookhart, M.A., Schneeweiss, S., Avorn, J., et al. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA 303 (2010), 857–864.
11. 11 Kainz, A., Mayer, B., Kramar, R., Oberbauer, R., Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients. Nephrol Dial Transplant 25 (2010), 3701–3706.
12. 12 Epogen (epoetin alfa) [package insert]. Thousand Oaks, CA; Amgen, Inc; 2011.
13. 13 Centers for Medicare & Medicaid Services, HHS. Medicare program; end-stage renal disease prospective payment system. Final rule. Fed Regist 75 (2010), 49029–49214.
14. 14 Fuller, D.S., Pisoni, R.L., Bieber, B.A., Gillespie, B.W., Robinson, B.M., The DOPPS Practice Monitor for US dialysis care: trends through December 2011. Am J Kidney Dis 61 (2013), 342–346.
15. 15 Gilbertson, D.T., Peng, Y., Arneson, T.J., Dunning, S., Collins, A.J., Comparison of methodologies to define hemodialysis patients hyporesponsive to epoetin and impact on counts and characteristics. BMC Nephrol, 14, 2013, 44.
16. 16 Aransep (darbepoetin alfa) [package insert]. Thousand Oaks, CA; Amgen, Inc; 2012.
17. 17 Johnson, D.W., Pollock, C.A., Macdougall, I.C., Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton) 12 (2007), 321–330.
18. 18 Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2 (2012), 279–335.
19. 19 Saran, R., Li, Y., Robinson, B., et al. US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 66:1 suppl 1 (2015), S1–S306.
20. 20 Suttorp, M.M., Hoekstra, T., Rotmans, J.I., et al. Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients. BMC Nephrol, 14, 2013, 200.
21. 21 Cotter, D., Zhang, Y., Thamer, M., Kaufman, J., Hernan, M.A., The effect of epoetin dose on hematocrit. Kidney Int 73 (2008), 347–353.
22. 22 Fujikawa, T., Ikeda, Y., Fukuhara, S., et al. Time-dependent resistance to erythropoiesis-stimulating agent and mortality in hemodialysis patients in the Japan Dialysis Outcomes and Practice Patterns Study. Nephron Clin Pract 122 (2012), 24–32.
23. 23 Schneider, A., Schneider, M.P., Scharnagl, H., et al. Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes. BMC Nephrol, 14, 2013, 67.
24. 24 Costa, N.A., Kshirsagar, A.V., Wang, L., Detwiler, R.K., Brookhart, M.A., Pretransplantation erythropoiesis-stimulating agent hyporesponsiveness is associated with increased kidney allograft failure and mortality. Transplantation 96 (2013), 807–813.
25. 25 Kiss, Z., Ambrus, C., Almasi, C., et al. Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis. Nephron Clin Pract 117 (2011), c373–c378.
26. 26 Grima, D.T., Dunn, E.S., Bernard, L.M., Mendelssohn, D.C., Impact of sevelamer versus calcium-based binders on hospitalizations and missed in-center dialysis treatments among CKD patients on dialysis: a modeled analysis. Curr Med Res Opin 29 (2013), 109–115.
27. 27 Ponka, P., Cellular iron metabolism. Kidney Int Suppl 69 (1999), S2–S11.
28. 28 Nakanishi, T., Kuragano, T., Kaibe, S., Nagasawa, Y., Hasuike, Y., Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations?. Clin Exp Nephrol 16 (2012), 819–826.